Brief: Calliditas Therapeutics Expands Licensing Agreement With Everest Medicine To South Korea
14/03/2022 06:08
March 14 (Reuters) - Calliditas Therapeutics CALTX.ST
* EXPANSION OF EVEREST MEDICINE'S LICENCE AGREEMENT TO
INCLUDE
SOUTH KOREA
* EXTENSION RESULTS IN UPFRONT PAYMENT OF USD 3 MILLION
* EXTENSION RESULTS IN ADDITIONAL PAYMENTS, ROYALTIES
RELATED TO
FUTURE POTENTIAL APPROVALS AND COMMERCIALISATION OF NEFECON IN
SOUTH KOREA
Source text for Eikon: ID:nWkr2PQfLD
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations